Atlas Trials

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Clinical trial NCT02142803 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02142803
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Adult GlioblastomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Uterine Corpus NeoplasmRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaSolid Neoplasm
Start date
2014-05-20
Primary completion
2020-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.